Quantcast

Latest Alimera Sciences Inc. Stories

2014-09-03 08:33:15

Sweden is latest country to grant marketing authorization ATLANTA, Sept. 3, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Swedish Medical Products Agency has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME)...

2014-08-07 16:29:18

ILUVIEN® Injections Increased over 25% in the United Kingdom on Sequential Basis from First Quarter 2014 ATLANTA, Aug. 7, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2014. "We achieved an important milestone during the second quarter of 2014 as...

2014-07-31 16:28:25

ATLANTA, July 31, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Danish Health and Medicines Authority has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available...

2014-07-28 16:26:45

Portugal approves reimbursement for ILUVIEN ATLANTA, July 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Norwegian Medicines Evaluation Board has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered...

2014-07-24 16:26:33

ATLANTA, July 24, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter of fiscal year 2014 financial results after the market close on Thursday, August 7, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by...

2014-06-30 08:29:57

ATLANTA, June 30, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries. Alimera submitted the application through the Mutual Recognition Procedure...

2014-06-23 08:27:39

ATLANTA, June 23, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to...

2014-05-27 16:25:30

ATLANTA, May 27, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Jefferies 2014 Healthcare Conference on Thursday, June 5, 2014 at 1:30 P.M. ET in New York, NY. The presentation will be webcast live and will be available for...

2014-05-08 16:27:04

ILUVIEN® Revenue Up Over 120% Sequentially from Fourth Quarter of 2013 ATLANTA, May 8, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2014. "We achieved solid revenue growth from sales of ILUVIEN during this first quarter of 2014 due to increasing...

2014-05-01 08:34:53

ATLANTA, May 1, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter of fiscal year 2014 financial results after the market close on Thursday, May 8, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by Dan...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'